NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled
NCT05179824 2025-05-06Tempus Priority Study: A Pan-tumor Observational StudyTempus AIActive not recruiting1,000 enrolled